Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

Photo of Trey Thoelcke
By Trey Thoelcke Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date.

We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corp. (NASDAQ: CELG), Dendreon Corp. (NASDAQ: DNDN), Gilead Sciences Inc. (NASDAQ: GILD), Illumina Inc. (NASDAQ: ILMN), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Pharmacyclics Inc. (NASDAQ: PCYC), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and VIVUS Inc. (NASDAQ: VVUS). We also tracked the iShares Nasdaq Biotechnology (NASDAQ: IBB) against the group.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest fell 10.0% between July 31 and August 15 to 5.28 million shares, the smallest number of shares sold short since the mid May reading.

Amgen Inc. (NASDAQ: AMGN) short interest fell 5.8% to 11.85 million shares. The average daily volume was the lowest it has been this year.

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) short interest rose 9.5% to 42.75 million shares. Days to cover has increased to 3.

Biogen Idec Inc. (NASDAQ: BIIB) short interest fell 8.4% to 2.24 million shares. The average daily volume was the lowest it has been this year.

Celgene Corp. (NASDAQ: CELG) short interest rose 1.5% to 6.40 million shares.

Dendreon Corp. (NASDAQ: DNDN) short interest rose 6.1% to 43.37 million shares. Short interest has been rising since the end of May, and days to cover is more than 8. Short interest is 28.8% of the float.

Gilead Sciences Inc. (NASDAQ: GILD) short interest rose 16.6% to 21.05 million shares, the greatest number of shares sold short so far this year.

Illumina Inc. (NASDAQ: ILMN) short interest rose 3.1% to 22.10 million shares. Days to cover is 25 and short interest is 18.3% of the float.

Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) short interest fell 3.2% to 5.74 million shares. Short interest was 9.1% of the float.

Pharmacyclics Inc. (NASDAQ: PCYC) short interest rose 9.1% to 5.33 million shares. Days to cover rose from 5 at the July 31 reading to 7 by August 15. Short interest was 9.8% of the float.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) short interest rose 0.1% to 4.97 million shares. Days to cover rose from 4 at the July 31 reading to 7.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) short interest rose 21.8% to 6.39 million shares. After falling in the previous four periods, short interest has risen again.

VIVUS Inc. (NASDAQ: VVUS) short interest rose 18.5% to 16.44 million shares, the highest number of shares sold short since mid March. Short interest was 16.5% of the float.

To show how the sector has held up: the iShares Nasdaq Biotechnology (NASDAQ: IBB) ETF closed at $134.83 on the same date. Its current 52-week range is $87.67 to $138.75.

Trey Thoelcke

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618